La bourse ferme dans 7 h 17 min

Sanofi (SAN.PA)

Paris - Paris Prix différé. Devise en EUR
Ajouter à la liste dynamique
84,55-0,32 (-0,38 %)
À partir de 09:57AM CET. Marché ouvert.

Sanofi

46, avenue de la Grande Arm e
Paris 75017
France
33 1 53 77 40 00
https://www.sanofi.com

Secteur(s)Healthcare
Secteur d’activitéDrug Manufacturers - General
Employés à temps plein91 573

Dirigeants clés

NomTitrePayerExercéAnnée de naissance
Mr. Paul HudsonCEO & Director3,75MS.O.1967
Mr. Jean-Baptiste Chasseloup de ChatillonExecutive VP & CFOS.O.S.O.1965
Ms. Madeleine RoachExecutive VP & Head of Business OperationsS.O.S.O.S.O.
Mr. Laurent GilhodesPrincipal Accounting Officer and Vice President of Corporate AccountingS.O.S.O.S.O.
Dr. Josephine FubaraChief Science Officer of Consumer Health CareS.O.S.O.S.O.
Eva Schaefer-JansenHead of Investor RelationsS.O.S.O.S.O.
Mr. Dante BeccariaGlobal Compliance Officer & VPS.O.S.O.S.O.
Mr. Roy PapatheodorouExecutive VP & General CounselS.O.S.O.1978
Mr. Josep CatllaHead of CommunicationsS.O.S.O.S.O.
Mr. Pierre ChancelSenior Vice President of Global Diabetes and Senior Vice President of Global MarketingS.O.S.O.1957
Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en EUR.

Description

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Sanofi en date du 28 novembre 2023 est 2. Les scores principaux sont Audit : 4; Société : 2; Droits des actionnaires : 6; Compensation : 2.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.